| Primary |
| Anaemia |
30.0% |
| Iron Deficiency Anaemia |
30.0% |
| Anemia |
15.0% |
| Iron Deficiency |
10.0% |
| Haematochezia |
5.0% |
| Serum Ferritin Decreased |
5.0% |
| Serum Sickness |
5.0% |
|
| Dyspnoea |
7.7% |
| Infusion Site Discolouration |
7.7% |
| Nausea |
7.7% |
| Pain In Extremity |
7.7% |
| Presyncope |
7.7% |
| Urticaria |
7.7% |
| Anaphylactic Reaction |
3.8% |
| Deep Vein Thrombosis |
3.8% |
| Hypotension |
3.8% |
| Incorrect Drug Administration Rate |
3.8% |
| Oedema Peripheral |
3.8% |
| Pallor |
3.8% |
| Paraesthesia |
3.8% |
| Pyrexia |
3.8% |
| Rash |
3.8% |
| Rash Maculo-papular |
3.8% |
| Refusal Of Treatment By Patient |
3.8% |
| Respiratory Depression |
3.8% |
| Somnolence |
3.8% |
| Swollen Tongue |
3.8% |
|
| Secondary |
| Product Used For Unknown Indication |
32.1% |
| Gastrointestinal Haemorrhage |
17.0% |
| Crohn's Disease |
11.3% |
| Nephrogenic Anaemia |
7.5% |
| Normochromic Normocytic Anaemia |
7.5% |
| Pneumonia |
7.5% |
| Iron Deficiency |
3.8% |
| Peritoneal Dialysis |
3.8% |
| Renal Transplant |
3.8% |
| Iron Deficiency Anaemia |
1.9% |
| Renal Failure Chronic |
1.9% |
| Therapeutic Skin Care Topical |
1.9% |
|
| Infusion Related Reaction |
35.3% |
| Cerebral Haemorrhage |
11.8% |
| Liver Disorder |
11.8% |
| Platelet Count Decreased |
11.8% |
| Adverse Drug Reaction |
5.9% |
| Application Site Vesicles |
5.9% |
| Pneumonia |
5.9% |
| Toxic Epidermal Necrolysis |
5.9% |
| Urticaria |
5.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.5% |
| Drug Use For Unknown Indication |
27.4% |
| Prophylaxis |
8.7% |
| Crohn's Disease |
5.4% |
| Arthritis Bacterial |
5.3% |
| Anaemia |
4.6% |
| Hypertension |
3.2% |
| Diabetes Mellitus |
3.0% |
| Nephrogenic Anaemia |
1.8% |
| Dyspepsia |
1.7% |
| Pain |
1.6% |
| Anticoagulant Therapy |
1.3% |
| Diarrhoea |
1.2% |
| Gastrooesophageal Reflux Disease |
1.2% |
| Peritoneal Dialysis |
1.2% |
| Osteomyelitis |
1.0% |
| Iron Deficiency Anaemia |
0.9% |
| Thrombosis Prophylaxis |
0.9% |
| Convulsion |
0.9% |
| Hepatic Neoplasm Malignant |
0.9% |
|
| Rhabdomyolysis |
19.7% |
| Therapeutic Response Decreased |
10.7% |
| Anti-erythropoietin Antibody Positive |
9.8% |
| Full Blood Count Decreased |
9.8% |
| Vomiting |
5.7% |
| Death |
4.9% |
| Drug Ineffective |
4.1% |
| Haemoglobin Decreased |
4.1% |
| Respiratory Tract Infection |
4.1% |
| Skin Induration |
3.3% |
| Weight Decreased |
3.3% |
| Drug Interaction |
2.5% |
| Hepatic Failure |
2.5% |
| Hypokalaemia |
2.5% |
| Nephrogenic Systemic Fibrosis |
2.5% |
| Paraparesis |
2.5% |
| Tracheo-oesophageal Fistula |
2.5% |
| Ventricular Tachycardia |
2.5% |
| Anaemia |
1.6% |
| Cardiac Failure Acute |
1.6% |
|
